Clinical commissioning policy: Dabrafenib and trametinib in the treatment of patients with BRAF-mutated anaplastic thyroid cancer

Document first published:
Page updated:
Publication type:

The combination of dabrafenib and trametinib is recommended to be available as a routine commissioning treatment option for anaplastic thyroid cancer (ATC) within the criteria set out in this document.